As of 5 Jul 2026, FDC Limited share price is ₹433.80. The stock opened at ₹434.50, compared to its previous close of ₹434.25. During today's trading session, FDC Limited share price moved in the range of ₹427.20 to ₹437.00, with an average price of ₹432.10 for the day. Looking at its last 52-week, the stock has touched a low of ₹312.95 and a high of ₹527.80. On the performance front, FDC Limited share price has increased by 3.40% over the last six months and is down 11.07% on a year-on-year basis.
| Name | Mkt Cap Cr | P/E | P/B | ROE | D/E | ROCE | Book Value | Div. Yield | Turnover | EPS(TTM) |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 4,49,048.00 | 39.02 | 5.37 | 13.74% | 0.61 | 17.33% | 93.24 | 0.85% | 0.56 | 10.90 |
| Divis Laboratories | 1,77,179.00 | 69.00 | 10.57 | 15.32% | 0.00 | 19.56% | 629.49 | 0.45% | 0.58 | 98.19 |
| Torrent Pharmaceuticals | 1,57,804.00 | 66.03 | 17.03 | 26.76% | 1.05 | 18.30% | 16.90 | 0.90% | 0.49 | 64.75 |
| Cipla | 1,17,642.00 | 25.47 | 2.87 | 11.79% | 0.00 | 15.66% | 2.89 | 1.06% | 0.49 | 43.52 |
| Dr. Reddy's Laboratories | 1,12,368.00 | 27.03 | 2.97 | 11.07% | 0.18 | 12.54% | 375.78 | 0.59% | 0.63 | 38.68 |
| Zydus Lifesciences | 1,10,651.00 | 21.60 | 4.08 | 18.59% | 0.31 | 17.35% | 235.25 | 0.09% | 0.39 | 35.38 |
| Lupin | 1,09,676.00 | 20.48 | 4.89 | 23.76% | 0.04 | 24.88% | 659.05 | 0.75% | 0.61 | 129.18 |
| Mankind Pharma | 1,02,729.00 | 53.00 | 6.30 | 11.74% | 0.34 | 13.13% | 397.02 | 0.04% | 0.54 | 49.37 |
| Aurobindo Pharma | 90,608.00 | 25.87 | 2.39 | 9.25% | 0.19 | 11.76% | 391.14 | 0.26% | 0.48 | 41.58 |
| Laurus Labs | 82,398.90 | 60.26 | 10.10 | 18.21% | 0.45 | 16.70% | 10.19 | 0.20% | 0.97 | 13.72 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹2,108.12 | ₹1,942.94 | ₹1,783.75 | ₹1,527.92 |
| Other Income | ₹90.66 | ₹101.63 | ₹49.86 | ₹76.09 |
| Total Revenue | ₹2,198.78 | ₹2,044.58 | ₹1,833.61 | ₹1,604.01 |
| Total Expenses | ₹1,841.56 | ₹1,648.36 | ₹1,575.80 | ₹1,314.62 |
| Profit Before Tax | ₹357.22 | ₹396.22 | ₹257.80 | ₹289.39 |
| Tax | ₹90.43 | ₹91.16 | ₹63.98 | ₹73.23 |
| Profit After Tax | ₹266.79 | ₹305.06 | ₹193.83 | ₹216.16 |
| EPS - Basic | ₹16.39 | ₹18.58 | ₹11.66 | ₹12.81 |
| EPS - Diluted | ₹16.39 | ₹18.58 | ₹11.66 | ₹12.81 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹357.22 | ₹396.22 | ₹257.80 | ₹289.39 |
| Income before WC changes | ₹332.44 | ₹345.04 | ₹262.12 | ₹262.91 |
| Change in Assets | ₹40.70 | -₹39.06 | -₹86.03 | -₹91.71 |
| Change in Liabilities | ₹47.23 | ₹18.71 | ₹56.13 | ₹69.98 |
| Change in WC | ₹87.94 | -₹20.35 | -₹29.91 | -₹21.72 |
| Cash flow from Operations | ₹317.57 | ₹220.77 | ₹154.91 | ₹161.65 |
| Cash flow from Investing | -₹199.51 | -₹17.08 | ₹11.13 | -₹144.57 |
| Cash flow from Financing | -₹92.12 | -₹202.16 | -₹179.95 | -₹9.84 |
| Total Cash Flow | ₹25.94 | ₹1.53 | -₹13.90 | ₹7.25 |
| Cash (Start of the year) | ₹25.42 | ₹23.89 | ₹37.73 | ₹30.43 |
| Cash (End of the year) | ₹51.47 | ₹25.42 | ₹23.89 | ₹37.73 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹1,625.09 | ₹1,401.60 | ₹1,317.88 | ₹1,270.02 |
| Current Assets | ₹1,088.72 | ₹1,066.49 | ₹1,025.06 | ₹1,000.19 |
| Total Assets | ₹2,713.80 | ₹2,468.09 | ₹2,342.94 | ₹2,270.20 |
| Current Liabilities | ₹361.64 | ₹310.62 | ₹311.56 | ₹272.16 |
| Net Current Asset | ₹727.08 | ₹755.87 | ₹713.50 | ₹728.03 |
| Non-Current Liabilities | ₹71.08 | ₹60.30 | ₹49.98 | ₹41.69 |
| Equity Capital | ₹2,281.08 | ₹2,097.17 | ₹1,981.40 | ₹1,956.36 |
| Total Equity & Liabilities | ₹2,713.80 | ₹2,468.09 | ₹2,342.94 | ₹2,270.20 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹2,070.11 | ₹1,916.19 | ₹1,777.03 | ₹1,518.97 |
| Other Income | ₹105.52 | ₹103.22 | ₹53.91 | ₹78.73 |
| Total Revenue | ₹2,175.63 | ₹2,019.40 | ₹1,830.94 | ₹1,597.70 |
| Total Expenses | ₹1,807.96 | ₹1,621.46 | ₹1,565.25 | ₹1,312.25 |
| Profit Before Tax | ₹367.67 | ₹397.95 | ₹265.69 | ₹285.45 |
| Tax | ₹94.05 | ₹90.78 | ₹64.72 | ₹65.82 |
| Profit After Tax | ₹273.63 | ₹307.16 | ₹200.97 | ₹219.64 |
| EPS - Basic | ₹16.81 | ₹18.70 | ₹12.09 | ₹13.01 |
| EPS - Diluted | ₹16.81 | ₹18.70 | ₹12.09 | ₹13.01 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹367.67 | ₹397.95 | ₹265.69 | ₹285.45 |
| Income before WC changes | ₹327.76 | ₹345.62 | ₹266.69 | ₹261.86 |
| Change in Assets | ₹42.19 | -₹38.27 | -₹81.61 | -₹91.21 |
| Change in Liabilities | ₹43.21 | ₹16.36 | ₹56.50 | ₹70.04 |
| Change in WC | ₹85.40 | -₹21.91 | -₹25.11 | -₹21.17 |
| Cash flow from Operations | ₹310.34 | ₹220.81 | ₹164.72 | ₹162.38 |
| Cash flow from Investing | -₹199.45 | -₹17.76 | ₹3.62 | -₹147.42 |
| Cash flow from Financing | -₹92.10 | -₹202.03 | -₹179.83 | -₹9.70 |
| Total Cash Flow | ₹18.79 | ₹1.02 | -₹11.49 | ₹5.26 |
| Cash (Start of the year) | ₹20.77 | ₹19.75 | ₹31.13 | ₹25.72 |
| Cash (End of the year) | ₹39.67 | ₹20.77 | ₹19.75 | ₹31.13 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹1,642.26 | ₹1,404.06 | ₹1,311.66 | ₹1,265.67 |
| Current Assets | ₹1,068.06 | ₹1,054.57 | ₹1,023.76 | ₹988.58 |
| Total Assets | ₹2,710.32 | ₹2,458.63 | ₹2,335.42 | ₹2,254.25 |
| Current Liabilities | ₹355.01 | ₹307.67 | ₹310.69 | ₹270.62 |
| Net Current Asset | ₹713.05 | ₹746.90 | ₹713.07 | ₹717.96 |
| Non-Current Liabilities | ₹68.12 | ₹53.76 | ₹43.99 | ₹34.94 |
| Equity Capital | ₹2,287.19 | ₹2,097.20 | ₹1,980.74 | ₹1,948.69 |
| Total Equity & Liabilities | ₹2,710.32 | ₹2,458.63 | ₹2,335.42 | ₹2,254.25 |
FDC Limited is an India-based company, which is principally engaged in the business of manufacturing and trading of pharmaceutical products. The Company is specialized in manufacturing Oral Rehydration Solutions (ORS), energy drinks, antibiotics and ophthalmic therapies. Its products include Albuterol Sulfate, Bromhexine Hydrochloride, Cinnarizine, Flunarizine Dihydrochloride, Flurbiprofen Sodium, Miconazole Nitrate, Timolol Maleate, Amoxycillin + Clavulanic Acid, Rupatadine Fumarate, Salbutamol Sulphate, Kaolin Light/ Pectin, among others. The Company’s product offerings cover an extensive range of categories, including anti-infectives, gastrointestinal treatments, ophthalmic, vitamins, minerals, dietary supplements, cardiovascular solutions, anti-diabetics, respiratory care, gynecology, dermatology and analgesics. Its various brands include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl and Mycoderm.
FDC Limited share price is ₹433.80 as on 03 Jul, 2026, 15:56 IST.
In the last 1 year, FDC Limited delivered a return of -11.07%. The FDC Limited share price hit a high of ₹527.80 and low of ₹312.95.
The Mutual Fund Shareholding in FDC Limited was 6.23% at the end of Mar 2026.
The 52-week high and low of FDC Limited share is ₹527.80 and ₹312.95 as of 03 Jul, 2026.
The market capitalisation of FDC Limited is ₹7,067.59 Crores as on 03 Jul, 2026.
The stock symbol of FDC Limited is FDC on the NSE, 531599 on the BSE, and the ISIN is INE258B01022.
FDC Limited shares closed yesterday at ₹434.25 on NSE & ₹434.10 on BSE
To buy FDC Limited shares, open a demat account with Upstox and complete the KYC process. Once your account is set up, search for the stock and place your order.
No, shares of FDC Limited or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell FDC Limited shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.
The PE and PB ratio of FDC Limited is 25.11 and 2.84 respectively, as on 03 Jul, 2026, 15:56 IST.